share_log

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K:重大事件
美股sec公告 ·  07/10 08:04
Moomoo AI 已提取核心訊息
Vivos Therapeutics, Inc., a company listed on The Nasdaq Stock Market, reported on July 10, 2024, that it has received approval from a Nasdaq Hearings Panel to continue its listing, contingent on demonstrating compliance with the stockholders' equity requirement by August 15, 2024. The company had previously been notified of non-compliance with Nasdaq's minimum equity requirement of $2.5 million as of March 31, 2024. Vivos Therapeutics addressed this issue by closing a $7.5 million equity private placement on June 10, 2024, and subsequently met with the Panel on June 27, 2024. The company is actively working to maintain compliance, exploring additional equity financing, and expects positive impacts on revenue and equity from a strategic marketing and distribution alliance. However, there is a risk of failing to maintain the required equity level, which could lead to delisting and materially affect the company's stock price and operations.
Vivos Therapeutics, Inc., a company listed on The Nasdaq Stock Market, reported on July 10, 2024, that it has received approval from a Nasdaq Hearings Panel to continue its listing, contingent on demonstrating compliance with the stockholders' equity requirement by August 15, 2024. The company had previously been notified of non-compliance with Nasdaq's minimum equity requirement of $2.5 million as of March 31, 2024. Vivos Therapeutics addressed this issue by closing a $7.5 million equity private placement on June 10, 2024, and subsequently met with the Panel on June 27, 2024. The company is actively working to maintain compliance, exploring additional equity financing, and expects positive impacts on revenue and equity from a strategic marketing and distribution alliance. However, there is a risk of failing to maintain the required equity level, which could lead to delisting and materially affect the company's stock price and operations.
納斯達克上市公司vivos therapeutics於2024年7月10日發佈公告稱,已獲得納斯達克聽證委員會批准繼續上市,前提是在2024年8月15日前證明其符合股東權益要求。該公司此前曾因未達到納斯達克的250萬美元最低股本要求,而於2024年3月31日被通知不符合規定。vivos therapeutics通過於2024年6月10日進行75萬美元的定向增發解決了此問題,並於2024年6月27日隨後與聽證委員會會面。該公司正在積極努力保持合規性,探索額外的股權融資,並預計將從戰略性的市場營銷和分銷聯盟中獲得營業收入和股東權益的積極影響。然而,若未能保持所需的股權水平,則可能導致退市並對公司的股價和業務產生實質性影響。
納斯達克上市公司vivos therapeutics於2024年7月10日發佈公告稱,已獲得納斯達克聽證委員會批准繼續上市,前提是在2024年8月15日前證明其符合股東權益要求。該公司此前曾因未達到納斯達克的250萬美元最低股本要求,而於2024年3月31日被通知不符合規定。vivos therapeutics通過於2024年6月10日進行75萬美元的定向增發解決了此問題,並於2024年6月27日隨後與聽證委員會會面。該公司正在積極努力保持合規性,探索額外的股權融資,並預計將從戰略性的市場營銷和分銷聯盟中獲得營業收入和股東權益的積極影響。然而,若未能保持所需的股權水平,則可能導致退市並對公司的股價和業務產生實質性影響。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息